logo
Twitter
Discord
Email
logo
BioLife Solutions, Inc.

BioLife Solutions, Inc.

NASDAQ•BLFS
CEO: Mr. Roderick de Greef
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Listing Date: 1989-11-22
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
Contact Information
3303 Monte Villa Parkway, Suite 310, Bothell, WA, 98021, United States
425-402-1400
www.biolifesolutions.com
Market Cap
$1.18B
P/E (TTM)
-365.0
74.9
Dividend Yield
--
52W High
$29.62
52W Low
$19.10
52W Range
51%
Rank62Top 92.6%
1.9
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.9 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$28.07M-8.19%
4-Quarter Trend

EPS

$0.01-127.10%
4-Quarter Trend

FCF

$2.80M-24.02%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Revenue Growth Strong Nine months revenue reached $77.43M, marking a 30% increase driven by product sales.
Operating Cash Flow Improved Net cash provided by operating activities was $15.20M for nine months, up from $6.79M prior.
Equity Position Strengthened Total shareholders' equity grew to $353.74M as of September 30, 2025, up from year-end 2024.
PanTHERA Acquisition Expensed Immediate $15.5M IPR&D expense recognized following the April 2025 PanTHERA asset acquisition.

Risk Factors

Operating Loss Widened Nine months operating loss deteriorated to $(17.95M) compared to $(5.02M) in the prior period.
Deferred Tax Asset Risk Management projects a full $56.8M valuation allowance against U.S. deferred tax assets due to uncertainty.
Contingency Loss Recorded Recorded $1.4M loss contingency related to customer claims from the discontinued Global Cooling business.
Term Loan Maturity Near Remaining Term Loan principal of $7.50M matures in June 2026, requiring future financing action.

Outlook

SAVSU Divestiture Completed SAVSU Transaction closed October 6, 2025, for $25.5M; accounting for divestiture is not yet finalized.
Sufficient Liquidity Expected Current cash levels are believed sufficient to meet liquidity needs for at least the next twelve months.
R&D Investment Increased Research and development expenses rose 27% for nine months, driven by increased personnel costs.
Stock Comp Costs Remaining $0.9M unrecognized non-cash compensation cost remains for performance-based awards vesting over 0.2 years.

Peer Comparison

Revenue (TTM)

STAAR Surgical CompanySTAA
$94.91B
+30136.8%
Neogen CorporationNEOG
$880.32M
-3.7%
NovoCure LimitedNVCR
$642.27M
+11.2%

Gross Margin (Latest Quarter)

Xeris Biopharma Holdings, Inc.XERS
85.2%
+10.3pp
STAAR Surgical CompanySTAA
82.2%
+17.6pp
NovoCure LimitedNVCR
73.2%
-3.9pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
NEOG$2.01B-3.3-26.9%23.6%
ESTA$1.96B-24.1-253.8%77.1%
AZTA$1.84B-30.8-3.5%2.5%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
-63.2%
Declining Profitability
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Next earnings:Mar 2, 2026
|
EPS:-$0.02
|
Revenue:-
Reports
All Years
  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 6, 2025|
    Revenue: $28.07M-8.2%
    |
    EPS: $0.01-127.1%
    Beat
  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 7, 2025|
    Revenue: $25.42M+28.9%
    |
    EPS: $-0.33-26.7%
    Miss
  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 8, 2025|
    Revenue: $23.94M+29.9%
    |
    EPS: $-0.01-95.7%
    Beat
  • Form 10-K/A - FY 2024

    Period End: Dec 31, 2024|Filed: Apr 8, 2025|
    Revenue: $82.25M-42.6%
    |
    EPS: $-0.44+71.1%
    Miss
  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 3, 2025|Refer to amended data
  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 12, 2024|
    Revenue: $30.57M+29.7%
    |
    EPS: $-0.04-94.5%
    Beat
  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 9, 2024|
    Revenue: $19.72M-50.1%
    |
    EPS: $-0.45+95.7%
    Miss
  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 10, 2024|
    Revenue: $18.43M-51.1%
    |
    EPS: $-0.22-31.3%
    Meet